Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model.
- Author:
Xue-Qing HU
1
;
Zhao-Hua JIANG
;
Ning-Fei LIU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; COS Cells; Cells, Cultured; Cercopithecus aethiops; Disease Models, Animal; Female; Gene Transfer Techniques; Genetic Therapy; Humans; Lymphedema; therapy; Mice; Mice, Inbred BALB C; Plasmids; Transfection; Vascular Endothelial Growth Factor C; genetics
- From: Chinese Journal of Plastic Surgery 2008;24(3):207-211
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effect of vascular endothelial growth factor C (VEGF-C) gene for chronic obstructive lymphedema in mouse tail model which may provide a new treatment for lymphedema.
METHODSRT-PCR and immunoabsorption were applied to detect VEGF-C gene expression in fibroblasts and secretion of VEGF-C protein in COS7 cells respectively after pCDNA3.1 (+) VEGF-C transfection. A mouse tail model of chronic obstructive lymphedema was created. Then the pcDNA3.1-VEGF-C plasmid was injected into the tail. The effect of modulating lymphangiogenesis was observed.
RESULTSCompared with control group, overexpression of VEGF-C enhanced lymphangiogenesis in vivo and mouse tail skin suffering chronic obstructive lymphedema was improved by VEGF-C gene significantly.
CONCLUSIONSVEGF-C can improve the lymphedema through enhancing lymphangiogenesis.
